708 POSTER AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors
Mita A, Wang D, Takimoto C, Martin D, Nguyen L, Rasmussen E, Storgard C, LoRusso P. 708 POSTER AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. European Journal Of Cancer Supplements 2007, 5: 109-110. DOI: 10.1016/s1359-6349(07)70507-4.Peer-Reviewed Original ResearchAMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors
Mita A, Wang D, Takimoto C, Malseed E, Nguyen L, Rasmussen E, Storgard C, LoRusso P. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2007, 25: 14033-14033. DOI: 10.1200/jco.2007.25.18_suppl.14033.Peer-Reviewed Original ResearchDose-limiting toxicityAMG 386Advanced solid tumorsComplete responsePK profilesAdult patientsSolid tumorsMedian age 59.5 yearsAntitumor activityOpen-label studyGemcitabine/cisplatinFurther clinical studiesFormation of antibodiesTumor response dataSerious AEsCancer refractoryFOLFOX-4Stable diseaseProgressive diseaseWeekly administrationTumor responseWeek 16Bladder cancerDisease progressionWeek 8